PacingCure develops gene therapies for common cardiac arrhythmias and cardiomyopathies, using an innovative precision approach. Our medical products offer patients who suffer from severe morbidity and mortality superior treatment over established implantable and medicinal therapies, and a cure for patients who are currently untreatable. Our in-vivo validated gene therapies are injected directly into a small region of the heart using a simple, minimal-invasive procedure. Using non-dilutive funding, PacingCure has developed proprietary technologies to support a portfolio of products. As we move ahead, we expect to secure a Series A investment to advance the technology and complete phase 1/2 clinical testing. PacingCure’s team builds on a longstanding track-record with highly experienced clinicians and scientists. With PacingCure’s unique platform and excellent team, it’s our vision to become a world leader in cardiac gene therapy.